Department of Drug Discovery, University of Miami, Miami, USA
Case Report
Personalized Drug Sensitivity Testing on a Pediatric Osteosarcoma Tumor Biopsy
Author(s): Ines Lohse*, Hassan Al-Ali, Giselle Dutcher, Warren Alperstein, Donald W. Coulter, Matteo Trucco, Jonathan C. Trent and Claes Wahlestedt
Precision medicine approaches using ex vivo Drug Sensitivity Testing (DST) have recently received attention in the cancer research community as a means to improve treatment stratification in populations where multiple treatment attempts are not feasible, or no standard treatment exists. This is particularly relevant for ultra-rare cancers such as osteosarcoma where population sizes preclude traditional prospective randomized clinical trials that can yield statistically meaningful data. DST has the potential to supplement existing patient stratification approaches by providing tumor-specific response data to aid in treatment selection at the time of treatment decision.
Here we present the case of a pediatric osteosarcoma patient who was evaluated using DST at the time of standard of care treatment. The DST screen indicated significant treatment sensitivity toward anthracyclin.. View More»
DOI:
10.35248/2471-8556.25.11(1).006